TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01938443
Drug: GSK2256098
Normalized name: GSK2256098
DrugBank: GSK2256098 (DB16106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
Study: NCT01938443
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
Study: NCT02204085
Drug: GO-203-2c
Normalized name: GO-203-2C
DrugBank: GO-203-2C (DB15008)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02204085
Drug: GO-203-2c + Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02392455
Drug: treatment
Normalized name: Acne Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel plus nintedanib until progression or intolerability
Study: NCT02008396
Drug: Midomafetamine HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Group 1 receive 75 or 100 mg during the two experimental sessions and participants in Group 2 receive 100 or 125 mg during two experimental sessions.
Study: NCT03760523
Drug: Minnelide
Normalized name: Minnelide
DrugBank: Minnelide (DB17309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
Study: NCT03055377
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)
Study: NCT02962999
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After induction, patients will be received 1 mg/kg ketamine bolus, then administered 0,5 mg/kg/hour ketamine infusion intraoperatively.
Study: NCT02962999
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively.
Study: NCT03265431
Drug: 18F-TPP
Normalized name: 18F-TPP
DrugBank: Bfpet F-18 (DB15424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging with 18-F-TPP (18F-BFPET)
Study: NCT01281592
Drug: LOR-253 HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: APTO-253 (DB17143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
Study: NCT01064973
Drug: arbaclofen
Normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
Study: NCT04256707
Drug: Selinexor 100 mg
Normalized name: selinexor 100 mg/week (20 mg x 5) ORAL TABLET
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100-mg 2 formulations:~* 5 × 20-mg tablets (Tablet A)~* 1 × 100-mg tablet (Tablet B)
Study: NCT04256707
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 IV
Study: NCT04256707
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg IV
Study: NCT04256707
Drug: Selinexor 40 mg
Normalized name: selinexor 40 MG
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: - 2 × 20-mg tablets (Tablet A)
Study: NCT04256707
Drug: Selinexor 80 mg
Normalized name: selinexor 80 mg/week (20 mg x 4) ORAL TABLET
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: - 4 × 20-mg tablets (Tablet A)
Study: NCT04256707
Drug: Selinexor 60 mg
Normalized name: selinexor 60 MG
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: - 3× 20-mg tablets (Tablet A)
Study: NCT01031368
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01031368
Drug: clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01031368
Drug: filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT01443039
Drug: phenotypical approach
Normalized name: Proliferation arrested myelomonocytic leukemic cell line-derived cells with a mature dendritic cell phenotype
DrugBank: DCP-001 (DB17423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =\>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
Study: NCT04301349
Drug: vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion
Study: NCT02049385
Drug: Diazoxide
Normalized name: Diazoxide
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A nondiuretic vasodilator thiazide-related agent
Study: NCT01522963
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
Study: NCT00532441
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
Study: NCT00532441
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
Study: NCT01868126
Drug: DE-117 ophthalmic solution
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01868126
Drug: latanoprost ophthalmic solution
Normalized name: Latanoprost Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00768040
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg once daily
Study: NCT00630760
Drug: NRX 194204
Normalized name: NRX-1074
DrugBank: NRX-1074 (DB11784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
Study: NCT00182793
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
Study: NCT00182793
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
Study: NCT00182793
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
Study: NCT00616005
Drug: Temodar and Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle \& every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, \& 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
Study: NCT02719028
Drug: Antroquinonol
Normalized name: Antroquinonol
DrugBank: Antroquinonol (DB12326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antroquinonol will be provided as capsules of 50 mg
Study: NCT03215030
Drug: Modakafusp alfa
Normalized name: Modakafusp alfa
DrugBank: Modakafusp alfa (DB16399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modakafusp alfa intravenous infusion.
Study: NCT03215030
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone.
Study: NCT03854552
Drug: BI 764198
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT04087967
Drug: Decitabine plus HAAG regimen
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine:20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~16,intravenous infusion; Aclarubicin:10mg/d, d3\~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;
Study: NCT04087967
Drug: Idarubicine plus Cytarabine regimen
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
Study: NCT01234142
Drug: varenicline free base patch
Normalized name: K201 free base
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: varenicline transdermal delivery system (12.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
Study: NCT01234142
Drug: varenicline free base patch
Normalized name: K201 free base
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: varenicline transdermal delivery system (18.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
Study: NCT01234142
Drug: varenicline free base patch
Normalized name: K201 free base
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: varenicline transdermal delivery system (24.0 mg payload \[drug amount loaded in each patch\]) will be applied to the skin once daily for 14 days
Study: NCT01234142
Drug: varenicline free base patch
Normalized name: K201 free base
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
Study: NCT00005990
Drug: tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005990
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01716585
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule (double-blind treatment period), tablet (open-label treatment period)
Study: NCT01716585
Drug: Placebo for ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule
Study: NCT03604159
Drug: Buprenorphine Extended Release
Normalized name: Buprenorphine Extended-Release Injection
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.
Study: NCT03604159
Drug: Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
Normalized name: buprenorphine Sublingual Tablet
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
Study: NCT00405756
Drug: Lenalidomide: Double-blind Induction
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Study: NCT05523323
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
Study: NCT00405756
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Study: NCT00405756
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Study: NCT00405756
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion
Study: NCT00405756
Drug: Lenalidomide: Double-blind Maintenance
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
Study: NCT00405756
Drug: Lenalidomide: Open-label
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
Study: NCT02934919
Drug: Nalmefene
Normalized name: Nalmefene
DrugBank: Nalmefene (DB06230)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
Study: NCT00656331
Drug: Amlodipine and Hydrocholorothiazide
Normalized name: aliskiren, amlodipine and hydrochlorothiazide
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
Study: NCT00372073
Drug: seliciclib
Normalized name: Seliciclib
DrugBank: Seliciclib (DB06195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg bid x 3 days every 2 weeks
Study: NCT02681523
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02088060
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol capsules
Study: NCT02088060
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine capsules
Study: NCT02088060
Drug: Placebo Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo cannabidiol capsules
Study: NCT02088060
Drug: Placebo Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo olanzapine capsules
Study: NCT04051320
Drug: Leuprolide Acetate 3.75 MG/ML
Normalized name: leuprolide acetate 3.75 MG/ML
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg/month leuprolide acetate intramuscular injection
Study: NCT04051320
Drug: Micronized progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg micronized progesterone tablets
Study: NCT02862275
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03830177
Drug: Natural Treatment
Normalized name: Natural Ice
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a topical treatment formulated with natural ingredients (Lactobacillus sp., honey, and turmeric) and a kit containing all necessary materials, including an instruction handout. The treatment is applied to the scalp, left for roughly 5 minutes, and rinsed off.
Study: NCT02159495
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02711891
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following lance one, 0.2 grams of loperamide 5% gel was applied from a sterile syringe to the participants previous lance site within an 8 mm diameter circular plastic mold. The loperamide gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The loperamide gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
Study: NCT03243201
Drug: Colloidal silver nanoparticles
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contains 10ppm colloidal silver nanoparticles
Study: NCT00667537
Drug: Radium-223 chloride (Xofigo®, BAY88-8223) injection
Normalized name: Radium-223 chloride
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
Study: NCT01045902
Drug: Avelox (Moxifloxacin, BAY12-8039)
Normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
Study: NCT01045902
Drug: Sulbactam/Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
Study: NCT00349960
Drug: NeoRecormon SC once-weekly versus once-every-other-week
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00091039
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00091039
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02552537
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
Study: NCT03721406
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ropivacaine administerd via thoracic paraveretebral catheter
Study: NCT02189239
Drug: Zeller Entspannung film coated tablet
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01295645
Drug: Cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
Study: NCT04768439
Drug: Low Dose Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a 200 IU/d vitamin D since they tolerate full enteral nutrition.
Study: NCT04768439
Drug: High Dose Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 1600 IU/d vitamin D since they tolerate full enteral nutrition.
Study: NCT02665039
Drug: Vinflunine
Normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinflunine will be given intravenously once every 21 days, starting at a dose of:~* 280 mg/m2 in patients with GFR 40-60 ml/min~* 250 mg/m2 in patients aged \>80 years and/or GFR 30-40 ml/min
Study: NCT02665039
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
Study: NCT02665039
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
Study: NCT03119428
Drug: OMP-313M32
Normalized name: Immunoglobulin g1, anti-(human receptor tigit(t-cell immunoreceptor with ig and itim domains)) (humanized mouse monoclonal omp-313m32 .gamma.1-chain), disulfide with humanized mouse monoclonal omp-313m32 .kappa.-chain, dimer
DrugBank: Etigilimab (DB18854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
Study: NCT03119428
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Human IgG4 anti-PD-1 monoclonal antibody
Study: NCT01632345
Drug: Doravirine
Normalized name: Doravirine
DrugBank: Doravirine (DB12301)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.